ChinaCourt CasesCourtsEIP Coffee BreakEIP Patent 101 CornerprosecutionSupreme People's Court
19 August 2021

Do Invention and UM Patents Filed on the Same Day Rise and Fall Together?

Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape

Seminal Cases by the SPC

Recently, the Intellectual Property Division of the Supreme People's Court (SPC) issued a list of seminal (精品) cases. Although China is not a case law country, such seminal cases issued by the SPC have high guiding impact for similar cases in the future, so they are still worthy of attention.

One of the seminal cases ((2020) 最高法知民终699号) is very interesting. It involves a set of “same day applications”, i.e. an invention patent and utility model (UM) patent directed towards the same invention filed on the same day. The key issue is: if the invention patent application is rejected, what happens to the corresponding granted UM?

A Bit of Background

China allows patent applicants to apply for Invention and UM patents for the same invention on the same day (same-day applications). Typically the UM grants first (within 5-8 months), allowing the patentee to initiate license agreements or enforcement actions based thereon. Then later, when (and if) the time-consuming and costly invention application finally proceeds to grant, the applicant can obtain an invention patent’s longer 20-year protection term by giving up the UM patent (10 year term). Applicants welcome this dual application strategy, since it provides fast and comprehensive protection for product inventions.

Same Day Applications

In this seminal case, the applicant had obtained a granted UM earlier, but the corresponding invention patent application had been finally rejected, even after a re-examination request and administrative suit. Later the patentee initiated an infringement lawsuit based on the same-day UM patent which protects an identical technical solution. The first instance held in favor of the patentee. The SPC revoked the judgment of the first instance and held that in this case, the patent right for the utility model should be questioned.

Generally speaking, if a same-day invention application is rejected for lacking novelty, then the related same-day UM patent must also lack novelty, and thus will not meet the grant requirements. However, if the invention application is rejected for lack of inventiveness, then the judge cannot directly arrive at the same conclusion, since inventiveness requirements for invention patents and UMs are different.

We believe that this judgment is reasonable and will effectively reduce litigation costs in similar situations. We are of view that this judgment will not have significant impact on the same-day filing strategy for high-quality inventions.

You may refer to our previous article regarding same-day filing strategy.

(http://ipc.court.gov.cn/m/detail.html?id=1410)

About the Authors

Yolanda Wang is a Principal, Chinese Patent Attorney, and Chinese Patent Litigator at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

Other Articles

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

30 April 2021
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

29 April 2021
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

10 March 2025
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

New Policies to Promote Importation of Innovative Drugs

8 November 2018
At the April 12, 2018 executive meeting of the State Council in China, Premier Mr. Li Keqiang indicated the government’s desire to increase China’s access to innovative drugs. To achieve this, the government would encourage importation of innovative drugs into China by streamlining the regulatory pathway, enhancing IP protection, and lowering the cost of medicine. […]

Our Past Events

Top crossarrow-right